Cloud DX (TSX-V:CDX, OTCQB:CDXFF) CEO Robert Kaul joined Steve Darling from Proactive to reveal an exciting development for the company. Cloud DX has secured a significant purchase order for up to 300 advanced Vitaliti Continuous Vital Sign Monitor Systems and related software, valued at approximately $770,000. These cutting-edge units will be manufactured at the company's facility in Kitchener, Ontario, and are slated for delivery by the end of the second quarter of 2024.
The purchase order stipulates a 50% deposit with the remaining balance to be settled upon delivery. During the interview, Kaul elaborated on the innovative features of the patented and patent-pending Vitaliti units. These state-of-the-art devices are earmarked for deployment in multi-site studies involving post-operative patients. The first of these studies will be conducted under a Health Canada Investigational Testing Authorization (ITA) in advance of securing full Health Canada licensing and FDA clearance. Post-surgery patients will be monitored remotely at home using Vitaliti, with the collected data slated for use in training generative artificial intelligence algorithms. These algorithms are expected to revolutionize healthcare outcomes by predicting and mitigating adverse events proactively.
This purchase order represents a significant milestone for Cloud DX, underscoring the growing demand for its innovative healthcare solutions. With the deployment of Vitaliti units in pivotal clinical studies, Cloud DX is poised to make substantial strides in advancing patient care and driving the adoption of predictive healthcare technologies. Stay tuned for further updates as Cloud DX continues to spearhead innovation in the healthcare sector.